Effects of immunonutrition in advanced human immunodeficiency virus disease: A randomized placebo-controlled clinical trial (Promaltia study)

Clinical Infectious Diseases

Volumn 68, Issue 1, 2019, Pages 120-130

  Serrano Villar, Sergio ^a   De Lagarde, Mariá ^b   Vázquez Castellanos, Jorge ^c   Vallejo, Alejandro ^a   Bernadino, José I ^d   Madrid, Nadia ^a   Matarranz, Mariano ^b   Diáz Santiago, Alberto ^a   Gutiérrez, Carolina ^a   Cabello, Alfonso ^e   Villar Garciá, Judit ^f   Blanco, José Ramón ^g   Bisbal, Otilia ^b   Sainz, Taliá ^d   Moya, Andrés ^c,h,i   Moreno, Santiago ^b   Gosalbes, Mariá José ^c,i   Estrada, Vicente ^j  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c Genomics and Health   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e Hospital Universitario   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g HOSPITAL SAN PEDRO   (Spain)

^h UNIVERSITY OF VALENCIA   (Spain)

ⁱ CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^j HOSPITAL CLÍNICO SAN CARLOS   (Spain)

more..

Author keywords

CD4 T cells; immunoactivation; inflammation; microbiota; probiotics

Indexed keywords

BIOLOGICAL MARKER; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PLACEBO; PMT 25341; SYNBIOTIC AGENT; ANTIRETROVIRUS AGENT; IMMUNOLOGIC FACTOR; PREBIOTIC AGENT; PROBIOTIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; BACTERIAL TRANSLOCATION; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; CLINICAL TRIAL; DIET THERAPY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; COMBINED MODALITY THERAPY; DIET THERAPY; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PLACEBOS; PREBIOTICS; PROBIOTICS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85056586425     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy414     Document Type: Article

References (43)

1. Mocroft A, Lundgren JD, Sabin ML, et al., Risk factors and outcomes for late presentation for HIV-positive persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 2013; 10:e1001510.
2. Sobrino-Vegas P, Moreno S, Rubio R, et al., Impact of late presentation of HIV infection on short-, mid- A nd long-term mortality and causes of death in a multicenter national cohort: 2004-2013. J Infect 2016; 72:587-96.
3. Antinori A, Coenen T, Costagiola D, et al; European Late Presenter Consensus Working Group. Late presentation of HIV infection: A consensus definition. HIV Med 2011; 12:61-4.
4. Trickey A, May MT, Vehreschild JJ, et al., Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: A collaborative analysis of cohort studies. Lancet HIV 2017; 4:e349-56.
5. Gandhi RT, McMahon DK, Bosch RJ, et al., ACTG A5321 Team. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. PLoS Pathog 2017; 13:e1006285.
6. Brenchley JM, Price DA, Schacker TW, et al., Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71.
7. Mavigner M, Cazabat M, Dubois M, et al., Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest 2012; 122:62-9.
8. Sandler NG, Douek DC. Microbial translocation in HIV infection: Causes, consequences and treatment opportunities. Nat Rev Microbiol 2012; 10:655-66.
9. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al., Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013; 5:193ra91.
10. Vazquez-Castellanos JF, Serrano-Villar S, Latorre A, et al., Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol 2015; 8:760-72.
11. Serrano-Villar S, Rojo D, Martinez-Martinez M, et al., Gut bacteria metabolism impacts immune recovery in HIV-infected individuals. EBioMedicine 2016; 8:203-16.
12. Somsouk M, Estes JD, Deleage C, et al., Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS 2015; 29:43-51.
13. Tenorio AR, Zheng Y, Bosch RJ, et al., Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014; 210:1248-59.
14. Gori A, Rizzardini G, Van't Land B, et al., Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the 'COPA' pilot randomized trial. Mucosal Immunol 2011; 4:1-10.
15. Cahn P, Ruxrungtham K, Gazzard B, et al; (BTE) Blinded Nutritional Study for Immunity and Tolerance Evaluation Study Team. The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-cell decline and immune activation: A 1-year multicenter randomized controlled double-blind trial in HIVinfected persons not receiving antiretroviral therapy (the BITE Study). Clin Infect Dis 2013; 57:139-46.
16. Asmuth DM, Ma ZM, Albanese A, et al., Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. AIDS 2013; 27:2207-17.
17. Somsouk M, Dunham RM, Cohen M, et al., The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: A randomized crossover trial. PLoS One 2014; 9:e116306.
18. Villar-Garcia J, Guerri-Fernandez R, Moya A, et al., Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial. PLoS One 2017; 12:e0173802.
19. Serrano-Villar S, Vazquez-Castellanos JF, Vallejo A, et al., The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects. Mucosal Immunol 2017; 10:1279-93.
20. Villar-Garcia J, Hernandez JJ, Guerri-Fernandez R, et al., Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIVtreated patients: A double-blind, randomized, placebo-controlled trial. J Acquir Immune Defic Syndr 2015; 68:256-63.
21. Grupo de estudio del SIDA/Plan nacional de salud (GESIDA/PNS). Guidelines for the use of antiretroviral agents in HIV-infected adults, 2016. Available at: https://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/publicaciones/profSanitarios/docTARGesidaPNS2013Def.pdf. Accessed 19 September 2016.
22. Caporaso JG, Kuczynski J, Stombaugh J, et al., QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010; 7:335-6.
23. Cole JR, Wang Q, Cardenas E, et al., The Ribosomal Database Project: Improved alignments and new tools for rRNA analysis. Nucleic Acids Res 2009; 37:D141-5.
24. Caporaso JG, Bittinger K, Bushman FD, DeSantis TZ, Andersen GL, Knight R. PyNAST: A flexible tool for aligning sequences to a template alignment. Bioinformatics 2010; 26:266-7.
25. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 2010; 26:2460-1.
26. Price MN, Dehal PS, Arkin AP. FastTree 2-approximately maximum-likelihood trees for large alignments. PLoS One 2010; 5:e9490.
27. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15:1369-77.
28. Irvine SL, Hummelen R, Hekmat S, Looman CW, Habbema JD, Reid G. Probiotic yogurt consumption is associated with an increase of CD4 count among people living with HIV/AIDS. J Clin Gastroenterol 2010; 44:e201-5.
29. Hummelen R, Hemsworth J, Changalucha J, et al., Effect of micronutrient and probiotic fortified yogurt on immune-function of anti-retroviral therapy naive HIV patients. Nutrients 2011; 3:897-909.
30. Hummelen R, Changalucha J, Butamanya NL, et al., Effect of 25 weeks probiotic supplementation on immune function of HIV patients. Gut Microbes 2011; 2:80-5.
31. Stiksrud B, Nowak P, Nwosu FC, et al., Reduced levels of D-dimer and changes in gut microbiota composition after probiotic intervention in HIV-infected individuals on stable ART. J Acquir Immune Defic Syndr 2015; 70:329-37.
32. Bindels LB, Delzenne NM, Cani PD, Walter J. Towards a more comprehensive concept for prebiotics. Nat Rev Gastroenterol Hepatol 2015; 12:303-10.
33. Generoso SV, Viana ML, Santos RG, et al., Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii. Eur J Nutr 2011; 50:261-9.
34. De-Souza DA, Greene LJ. Intestinal permeability and systemic infections in critically ill patients: Effect of glutamine. Crit Care Med 2005; 33:1125-35.
35. Viana ML, Santos RG, Generoso SV, Arantes RM, Correia MI, Cardoso VN. Pretreatment with arginine preserves intestinal barrier integrity and reduces bacterial translocation in mice. Nutrition 2010; 26:218-23.
36. Barham JB, Edens MB, Fonteh AN, Johnson MM, Easter L, Chilton FH. Addition of eicosapentaenoic acid to gamma-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. J Nutr 2000; 130:1925-31.
37. Aziz M, Livak B, Burke-Miller J, et al., Vitamin D insufficiency may impair CD4 recovery among Women's Interagency HIV Study participants with advanced disease on HAART. AIDS 2013; 27:573-8.
38. Majano P, Alonso-Lebrero JL, Janczyk A, et al., AM3 inhibits LPS-induced iNOS expression in mice. Int Immunopharmacol 2005; 5:1165-70.
39. Vital M, Karch A, Pieper DH. Colonic butyrate-producing communities in humans: An overview using omics data. mSystems 2017; 2. doi:10.1128/mSystems.00130-17.
40. Mutlu EA, Keshavarzian A, Losurdo J, et al., A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog 2014; 10:e1003829.
41. Ling Z, Jin C, Xie T, Cheng Y, Li L, Wu N. Alterations in the fecal microbiota of patients with HIV-1 infection: An observational study in a Chinese population. Sci Rep 2016; 6:30673.
42. Rocafort M, Noguera-Julian M, Guillen Y, et al., The gut microbiota correlates with HIV control and immune status. Abstract 261. In: Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 23-26 February 2015.
43. Lundgren JD, Babiker AG, Gordin F, et al; INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373:795-807.